{"title":"Chemokines are Underestimated in Preventing the Metastasizing and The Immune Elimination of Ovarian Cancer","authors":"R. Torensma, P. Zusterzeel","doi":"10.31487/J.ACO.2019.04.04","DOIUrl":null,"url":null,"abstract":"Nowadays the positive immune involvement in the eradication of tumor cells is assigned to the adaptive\nimmune response. By awakening of in vivo responding T cells that are suppressed by the tumor and prevents\nimmunological cure of the cancer. Normally activated T cells are well-ordered by several late occurring\ninhibitors to contain the response to the unknown invaders and spare the normal cells. The tumor strengthens\nthis inhibitory response to escape from immune elimination. Immunotherapy is to unleash the full capacity\nof the adaptive immune system by blocking this inhibitor response by monoclonal antibodies but with the\npotential drawback of autoimmune phenomena. Cytokines and chemokines became in oblivion after their\nsuspected necrosis of the tumor (TNF) did not fulfil their initial hope. Ovarian cancer is in most cases\nalready metastasized to the peritoneum and omentum. Here, we show that on the one hand chemokines\nproduced by Th2, CD8 and NK cells inhibit cancer spreading and thus leads to a better operability and better\nsurvival. Chemokine receptors are expressed by the tumor that are a decoy by binding chemokines that\nnormally should attract antigen cross-presenting dendritic cells that start an enforced T cell response to\nreplace the exhausted T cells","PeriodicalId":320563,"journal":{"name":"Annals of Clinical Oncology","volume":"5 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31487/J.ACO.2019.04.04","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Nowadays the positive immune involvement in the eradication of tumor cells is assigned to the adaptive
immune response. By awakening of in vivo responding T cells that are suppressed by the tumor and prevents
immunological cure of the cancer. Normally activated T cells are well-ordered by several late occurring
inhibitors to contain the response to the unknown invaders and spare the normal cells. The tumor strengthens
this inhibitory response to escape from immune elimination. Immunotherapy is to unleash the full capacity
of the adaptive immune system by blocking this inhibitor response by monoclonal antibodies but with the
potential drawback of autoimmune phenomena. Cytokines and chemokines became in oblivion after their
suspected necrosis of the tumor (TNF) did not fulfil their initial hope. Ovarian cancer is in most cases
already metastasized to the peritoneum and omentum. Here, we show that on the one hand chemokines
produced by Th2, CD8 and NK cells inhibit cancer spreading and thus leads to a better operability and better
survival. Chemokine receptors are expressed by the tumor that are a decoy by binding chemokines that
normally should attract antigen cross-presenting dendritic cells that start an enforced T cell response to
replace the exhausted T cells